Follow the Data Bivalirudin (and Not Heparin Alone) During Percutaneous Coronary Intervention Provides the Best Clinical Outcomes

被引：6
|
作者：
Stone, Gregg W. [1 ]
Mehran, Roxana [2 ,3 ]
Steg, Philippe Gabriel [4 ,5 ]
机构：
[1] Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY 10022 USA
[2] Mt Sinai Med Ctr, New York, NY 10029 USA
[3] Cardiovasc Res Fdn, New York, NY USA
[4] Univ Paris Diderot, Sorbonne Paris Cite, Hop Bichat, AP HP,INSERM U 1148,DHU FIRE, Paris, France
[5] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Lung & Heart Inst, Inst Cardiovasc Med & Sci, London, England
来源：
JACC-CARDIOVASCULAR INTERVENTIONS | 2015年 / 8卷 / 01期
关键词：
bivalirudin; heparin; coronary artery disease; percutaneous coronary intervention; ELEVATION MYOCARDIAL-INFARCTION; ABCIXIMAB; STRATEGIES; RISK;
D O I：
10.1016/j.jcin.2014.10.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：225 / 227
页数：3
相关论文
共 50 条
  • [21] Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
    Wang, Guiping
    Qi, Kaijie
    Li, Xuyang
    Zuo, Shuping
    Zhang, Ruolin
    Zhao, Yanan
    Sun, Suya
    Zhang, Juanjuan
    Liu, Xiaokun
    CARDIOVASCULAR THERAPEUTICS, 2024, 2024 (01)
  • [22] Bivalirudin during percutaneous coronary intervention in acute coronary syndromes
    Laine, Marc
    Lemesle, Gilles
    Dabry, Thibaut
    Panagides, Vassili
    Peyrol, Michael
    Paganelli, Franck
    Bonello, Laurent
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (03) : 295 - 304
  • [23] Bivalirudin Versus Heparin Alone in Low-Risk Percutaneous Coronary Intervention: Indirect Versus Direct Comparison
    Kaul, Sanjay
    Azarbal, Babak
    Shah, Prediman K.
    Diamond, George A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A343 - A343
  • [24] The clinical and economic impact of bivalirudin for percutaneous coronary intervention
    Malik, Nikesh
    Gershlick, Anthony H.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (06) : 699 - 706
  • [25] Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention
    Shah, Rahman
    Jovin, Ion S.
    Chaudhry, Amina
    Haji, Showkat A.
    Askari, Raza
    Dennis, Mallie M.
    Berzingi, Chalak
    Rao, Sunil V.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2019, 93 (02) : 241 - 247
  • [26] Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding
    Feldman, Alexander
    Suleiman, Khalid
    Bushari, Limor
    Yahalom, Malka
    Rozner, Ehud
    Freedberg, Nahum Adam
    Turgeman, Yoav
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2014, 23 (04) : 227 - 232
  • [27] Bivalirudin versus heparin during percutaneous coronary intervention: a meta-analysis of randomized trials
    Cassese, Salvatore
    Byrne, Robert
    Schunkert, Heribert
    Berger, Peter B.
    Kastrati, Adnan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (11) : B135 - B135
  • [28] BIVALIRUDIN VERSUS HEPARIN MONOTHERAPY IN PERCUTANEOUS CORONARY INTERVENTION PATIENTS: AN ANALYSIS OF ACUTE ADVERSE OUTCOMES AND COST
    Ephrem, Georges
    Guenoun, Jonathan
    Kim, Michael
    Jauhar, Rajiv
    Meraj, Perwaiz
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A115 - A115
  • [29] Should bivalirudin replace heparin during percutaneous coronary interventions?
    Antman, EM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (07): : 903 - 905
  • [30] Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom
    Sirker, Alex
    Mamas, Mamas
    Robinson, Derek
    Anderson, Simon G.
    Kinnaird, Tim
    Stables, Rod
    de Belder, Mark A.
    Ludman, Peter
    Hildick-Smith, David
    EUROPEAN HEART JOURNAL, 2016, 37 (16) : 1312 - 1320
12345